EGFR and lung cancer: Dasatinib is only effective in killing EGFR mutant cells [9], which accounts for 10% of NSCLCs; therefore, the observation that lung cancers can be manipulated to render them sensitive to killing by dasatinib could have important implications for devising innovative and potentially more efficacious treatment strategies for this disease.